On July 22, 2026, Dr. Reddy's Laboratories Limited released its unaudited consolidated financial results for the quarter ending June 30, 2026, as per the exchange filings.
The company reported a total revenue of ₹8,454.50 crore and net profit of ₹435.60 crore for the quarter ending June 30, 2026.
For the June 2026 quarter, Dr. Reddy's Laboratories reported a total income of ₹8,454.50 crore. This represents a 4.6% decline compared to ₹8,862.40 crore in the same quarter of the previous year.
However, there was a 5.4% increase from the March 2026 quarter, where the total income was ₹8,021.80 crore.
Net profit after taxes for the June 2026 quarter stood at ₹435.60 crore. This marks a 69.1% decrease from ₹1,409.90 crore in the June 2025 quarter.
Despite this year-on-year decline, the net profit showed a 96.8% rise from ₹221.30 crore in the March 2026 quarter.
For the financial year 2026, Dr. Reddy's Laboratories reported a total income of ₹35,058.60 crore. The net profit after taxes for the same period was ₹4,157.60 crore.
Read More: Eternal Share Price in Focus After Q1 FY27 Earnings Results: Total Income Up 173.7% YoY!
Dr. Reddy's Laboratories is a major global pharmaceutical company based in Hyderabad, India, founded in 1984 by Dr. Kallam Anji Reddy. It manufactures and markets a vast range of affordable and innovative medicines, operating in over 60 countries.
As of July 23, 2026, at 10:14 AM, Dr. Reddy's Laboratories share price on NSE was trading at ₹1,148.40, down by 2.91% from the previous closing price.
Dr. Reddy's Laboratories reported a 4.6% YoY decline in revenue to ₹8,454.50 crore for Q1 FY27, with a 69.1% YoY drop in net profit to ₹435.60 crore. However, both revenue and net profit showed QoQ growth compared to the March 2026 quarter.
For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 23, 2026, 10:53 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
